Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT ID: NCT06109441
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
50 participants
INTERVENTIONAL
2023-12-04
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
NCT03298022
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
NCT01461317
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03653026
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02171429
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE. Upon successful completion of the Screening Phase, subjects will return to the clinic for their first visit, which must occur within 28 days of the initial Screening Visit. Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268, followed by a weekly maintenance dose of ALTB-268 in the 12-week Induction Study Phase. Participants entering the maintenance study phase will continue to receive the SC dose of ALTB-268 every two weeks, up to week 52. Upon completion of the maintenance study phase, study participants will be asked to return for an end of study visit in approximately 4 weeks unless they continue in an open-label extension (OLE).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALTB-268
ALTB-268 IP will be administered via subcutaneous injection. One loading dose will be followed by 10 weekly doses of ALTB-268 in the 12 weeks induction study phase. Additional 20 biweekly doses of ALTB-268 will be administered in the 40 week maintenance study period.
ALTB-268
ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALTB-268
ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing to provide informed consent and to be compliant with the schedule of study visits and protocol assessments.
3. Diagnosis of UC established at least 12 weeks prior to Screening by standard clinical and endoscopic evidence and corroborated by a histopathology report.
4. Moderately to severely active UC, at the time of Screening, defined as a modified Mayo Score (mMS) of 5-9, inclusive, with an endoscopic subscore of ≥ 2 (from central reading), and a rectal bleeding (RB) subscore of ≥ 1.
5. Evidence of active UC, extending proximal to the rectum with ≥ 15 cm of involved colon.
6. Stable doses of concomitant medications:
1. Subjects receiving oral corticosteroids for the treatment of UC must be on a stable dose of ≤ 20 mg/day (prednisone or equivalent), or ≤ 9 mg/day budesonide. This dose must be stable from the initial Screening visit until the end of the Induction Phase.
2. Subjects receiving oral 5-aminosalicylic acid (5-ASA) must be on a stable dose from the initial Screening visit until the end of study.
3. Subjects receiving immunosuppressants (azathioprine, 6-mercaptopurine \[6-MP\] or methotrexate) must be on a stable dose for 4 weeks prior to Screening until the end of study treatment. Subjects taking methotrexate are also advised to take folic acid 5 mg/week (or equivalent) if there is no contraindication.
4. Subjects receiving probiotics must be on a stable dose from the initial Screening visit until the end of study.
5. Subjects receiving an anti-diarrhetic must be on a stable dose for ≥ 2 weeks prior to Screening until the end of study.
7. Previous treatment with one or two advanced therapy that demonstrated an inadequate response and/or loss of response.
8. Negative pregnancy test during Screening and Day 1 (V0) in females of childbearing potential.
9. Females with reproductive potential must be sexually abstinent or be willing to use a highly effective method of contraception from study start to ≥ 3 months after the final dose of the study drug. Highly effective methods of contraception include:
1. Hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); male partner should use a condom;
2. Intrauterine device or system; or
3. Surgical sterilization or partner sterile (must have documented proof).
10. Male subjects must be either surgically sterile (must have documented proof), agree to be sexually abstinent, or use a double-barrier method of birth control (e.g., condom and diaphragm with spermicide, condom with cervical cap and spermicide) from first study drug administration to ≥ 3 months after the final dose administration.
11. Male subjects must agree to refrain from donating sperm from first study drug administration to ≥ 3 months after final dose administration.
Exclusion Criteria
2. Ulcerative colitis limited to the rectum (ulcerative proctitis).
3. Presence of short bowel syndrome.
4. History of colectomy, or presence of an ileostomy or colostomy.
5. History of, or active colonic mucosal dysplasia.
6. Treatment with any intravenous (IV) corticosteroid or rectal therapy during the Screening period.
7. Treatment with any calcineurin inhibitor (e.g., cyclosporine, tacrolimus) from the initial Screening visit.
8. Treatment with NSAIDs within 4 weeks prior to Screening. Short-term use (\<7 days) of NSAIDs for non-UC related symptoms is allowed.
9. Treatment with tofacitinib or other Janus Kinase (JAK) inhibitors from the initial Screening visit.
10. Treatment with sphingosine-1-phosphate receptor (S1PR) modulators from the initial Screening visit.
11. Biologic therapy within 56 days or 5 half-lives (whichever is longer) prior to Screening. Confirmation of undetectable or non-therapeutic serum levels, as assessed by the Investigator, will allow for eligibility.
12. Tube feeding, defined formula diets, or parenteral alimentation/nutrition within 3 weeks of first dosing.
13. Treatment with oral antibiotics within 4 weeks prior to Screening or IV antibiotics within 8 weeks prior to Screening.
14. Vaccination with a live or live-attenuated vaccine within 4 weeks prior to Screening.
15. History of dysplasia or malignancy in the past 5 years, except completely excised basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
16. Subjects with a current or recent history of severe, progressive, or uncontrolled cardiac (including uncontrolled hypertension), renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological (e.g., history of seizures) disease, or any other severe comorbidity that, in the opinion of the Investigator, could confound the study results or put the subject at unreasonable risk.
17. Significant screening electrocardiogram (ECG) abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block.
18. For males, a QTc interval (Fridericia's correction) of \>450 ms, and for females, a QTc interval (Fridericia's correction) of \>470 ms.
19. Any of following laboratory abnormalities during the Screening period. If values are initially outside prescribed limits, the evaluation may be repeated once within the Screening period to determine eligibility:
1. Calculated creatinine clearance \< 60 mL/min
2. Serum transaminases \> 2.0x Upper Limit Normal (ULN)
3. Alkaline phosphatase (ALP) \> 2.0x ULN
4. Bilirubin \> 1.5x ULN; does not apply to subjects with Gilbert's Syndrome (Meulengracht Syndrome)
5. Hemoglobin \< 8g/dL
6. Platelets \< 75,000/μL
7. Absolute neutrophil count \< 1,500/ μL
8. Absolute lymphocyte count \< 800/ μL
20. Human immune deficiency virus (HIV) infection or known HIV-related malignancy.
21. Acute or chronic hepatitis B (HBV) or hepatitis C (HCV), or carrier status. Subjects with anti-HBc (hepatitis B core) antibodies (Ab) but with undetectable anti-HBs (hepatitis B surface) Ab should be excluded.
22. Positive immunoglobulin M (IgM) Ab titers in the presence of negative immunoglobulin G (IgG) Ab titers to Epstein-Barr virus (EBV).
23. Positive stool test for ova or parasites, positive stool culture for pathogens, or positive stool toxin assay for Clostridium difficile at Screening.
24. Active cytomegalovirus (CMV) infection at Screening, as assessed by the Investigator.
25. Positive QuantiFERON® TB test at Screening for latent Mycobacterium tuberculosis (TB) infection. If a QuantiFERON® TB test is indeterminate, the test should be repeated. If the result is again indeterminate, the subject should be excluded.
Subjects with a history of latent TB infection who received or are receiving an appropriate and documented course of therapy can be included if the screening examination and a chest x-ray performed within 3 months prior to Screening revealed no evidence of current active infection.
26. History of any opportunistic infection within 12 weeks of first dosing.
27. Any current or recent symptoms/signs of infection, except nasopharyngitis, within 4 weeks of first dosing.
28. Cirrhosis or active alcohol abuse, pr the judgment of the Investigator.
29. History of drug abuse according teo the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria within 12 months prior to Screening or a positive drug screening test.
30. Currently breast feeding, or pregnant.
31. Known hypersensitivity or intolerance to ALTB-268 or any of its excipients.
32. Participation in another clinical trial AND having received investigational medication within 30 days or 5 half-lives (whichever is longer) prior to Screening or having used an investigational device treatment within 30 days prior to Screening. Concurrent participation in an observational or long-term follow-up study and not actively receiving an investigational drug or device treatment may be eligible for participation in this study.
33. Inability to comply with the study protocol, in the opinion of the Investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AltruBio Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Lin, MD, PhD
Role: STUDY_DIRECTOR
AltruBio Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Diego Gastroenterology
San Diego, California, United States
Rocky Mountain Gastroenterology
Littleton, Colorado, United States
Gastro Health Research
Miami, Florida, United States
Digestive and Liver Center of Florida, LLC
Orlando, Florida, United States
Alliance Clinical Research of Tampa, LLC.
Tampa, Florida, United States
Gastro Health Partners Southern Indiana
New Albany, Indiana, United States
Gastro Health Partners Louisville
Louisville, Kentucky, United States
Louisiana Research Center, LLC.
Shreveport, Louisiana, United States
Gastroenterology Associates of North Mississippi
Oxford, Mississippi, United States
New York Presbyterian Hospital - Weill Cornell Medical Colllege
New York, New York, United States
Gastroenterology Group of Rochester
Rochester, New York, United States
Digestive Disease Medicine of Central New York
Utica, New York, United States
Dayton Gastroenterology, LLC
Beavercreek, Ohio, United States
Gastro Health Ohio
Liberty Township, Ohio, United States
Frontier Clinical Research, LLC
Uniontown, Pennsylvania, United States
Gastroenterology Associates, P.A.
Greenville, South Carolina, United States
DHAT / GI Aliance
Garland, Texas, United States
Caprock Gastro Reasearch
Lubbock, Texas, United States
GI Alliance
Mansfield, Texas, United States
Southern Star Research Institute LLC
San Antonio, Texas, United States
Tyler Research Institute
Tyler, Texas, United States
GI Alliance
Webster, Texas, United States
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, United States
Wellness Clinical Research, LLC
Vega Baja, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALTB-268-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.